Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2025-03-16 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TLX 6 pages 19.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new ordinary shares related to a contractual milestone payment. The document includes specifics about the number of securities, issue date, consideration, and compliance with listing rules. It is not a financial report, earnings release, or management discussion, but rather a formal announcement related to capital changes and securities quotation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the announcement itself, not a report publication or regulatory filing.
2025-03-16 English
Cleansing Notice 1 page 118.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issuance of shares as earn-out consideration related to an acquisition. It is a formal regulatory announcement about share issuance without disclosure under Part 6D.2 of the Corporations Act. The document is short (1563 characters) and does not contain financial statements or detailed financial data. It is not an annual report, interim report, or earnings release. It is not a report publication announcement since it contains substantive regulatory information about share issuance. The content fits the category of Share Issue/Capital Change announcements, which cover new share issues and related disclosures.
2025-03-16 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-03-12 English
Telix Completes FAP-Targeting Theranostic Acquisition 3 pages 145.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 12 March 2025, detailing the completion of an acquisition of FAP-targeting theranostic candidates. It describes the transaction terms, strategic rationale, and forward-looking statements about the company's plans. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a capital transaction (acquisition) expanding the company's pipeline. It is not a full annual or interim report, earnings release, or regulatory filing of financial results. The content fits best under Capital/Financing Update (CAP) as it relates to acquisition and financing terms of the transaction.
2025-03-11 English
App 3Y Change of Director Interests - C Behrenbruch 3 pages 303.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including shares, options, and performance rights. The content focuses on the director's personal share transactions and interests, including disposals and lapses of securities. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure of insider trading activity by a director, which aligns with the definition of 'Director's Dealing' filings. Therefore, the correct classification is DIRS (Director's Dealing).
2025-03-11 English
Notification of cessation of securities - TLX 4 pages 15.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse or cessation of certain securities (share rights and share appreciation rights) for Telix Pharmaceuticals Limited. It includes specific ASX security codes, numbers of securities ceased, reasons for cessation, and dates. The document is a formal announcement to the ASX about changes in the company's issued capital due to securities lapsing. It does not contain financial statements, management discussion, or other report content. It is a regulatory announcement about securities cessation, which fits the category of Major Shareholding Notification or similar. However, since it is about cessation of securities (not shareholding threshold changes), the closest fitting category is Major Shareholding Notification (MRQ) or Regulatory Filings (RNS). Given the specificity to securities cessation and ASX Appendix 3H form, the best classification is Regulatory Filings (RNS) as a general regulatory announcement about securities cessation, not a shareholding threshold change or capital change announcement. The document length is 8547 characters, so it is not a brief notice but a detailed regulatory filing. Therefore, the classification is RNS with high confidence.
2025-03-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.